title: Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients.
abstract: PURPOSE: We evaluated the clinical benefit of an allogeneic melanoma cell lysate (MCL)-pulsed autologous dendritic cell (DC) vaccine in advanced colorectal cancer patients expressing at least one of six MAGE-A antigens overexpressed by the cell line source of the lysate. EXPERIMENTAL DESIGN: DCs were cultured from peripheral blood mononuclear cells (PBMC), pulsed with the allogeneic MCL, and matured using cytokines that achieved high CD83- and CCR7-expressing DCs. Each patient received up to 10 intradermal vaccinations (3-5 x 10(6) cells per dose) at biweekly intervals. RESULTS: Twenty patients received a total of 161 vaccinations. Treatment was well tolerated and quality of life measurements did not vary much across time. One patient experienced partial response [5%; 95% confidence interval (CI), 1-24%] and seven achieved stable disease (35%; 95% CI, 18-57%), one of whom also achieved late tumor regression, yielding a clinical benefit response rate of 40% (95% CI, 22-61%). Although overall median progression-free survival was 2.4 months (95% CI, 1.9-4.1 months), five patients (25%) experienced prolonged progression-free survival (>6 months), two of whom (10%) remain progression-free for >27 and >37 months, respectively. This result is particularly meaningful as all patients had progressive disease before treatment. Overall, DC vaccination was associated with a serial decline in regulatory T cells. Using an antibody array, we characterized plasma protein profiles in responding patients that may correlate with vaccine activity and report a prevaccination protein signature distinguishing responders from nonresponders. CONCLUSION: This phase II vaccine study using mature, MCL-pulsed DCs has shown promising results and warrants further evaluation in a prospective randomized setting. (Clin Cancer Res 2009;15(24):7726-36).
authors.affiliation: Authors' Affiliations: Department of Medical Oncology, National Cancer Centre, Singapore; DanDrit Biotech A/S, Copenhagen, Denmark; Singapore General Hospital, Singapore; and The Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Han Chong
authors.initials: HC
authors.lastname: Toh
authors.forename: Who-Whong
authors.initials: WW
authors.lastname: Wang
authors.forename: Whay Kuang
authors.initials: WK
authors.lastname: Chia
authors.forename: Pia
authors.initials: P
authors.lastname: Kvistborg
authors.forename: Li
authors.initials: L
authors.lastname: Sun
authors.forename: Kelly
authors.initials: K
authors.lastname: Teo
authors.forename: Yee Peng
authors.initials: YP
authors.lastname: Phoon
authors.forename: Yatanar
authors.initials: Y
authors.lastname: Soe
authors.forename: Sze Huey
authors.initials: SH
authors.lastname: Tan
authors.forename: Siew Wan
authors.initials: SW
authors.lastname: Hee
authors.forename: Kian Fong
authors.initials: KF
authors.lastname: Foo
authors.forename: Simon
authors.initials: S
authors.lastname: Ong
authors.forename: Wen Hsin
authors.initials: WH
authors.lastname: Koo
authors.forename: Mai-Britt
authors.initials: MB
authors.lastname: Zocca
authors.forename: Mogens H
authors.initials: MH
authors.lastname: Claesson